The parent company of newly acquired ophthalmic device manufacturer Ellex has announced the appointment of a new CEO, with the entity officially taking over the distribution of Quantel Medical equipment in Australia this month.
French firm Lumibird Group acquired Ellex-branded lasers and ultrasound for $100 million last year and has since merged the business with its existing ophthalmic lasers and ultrasound subsidiary, Quantel Medical.
Ellex’s integration of the Quantel Medical product portfolio in Australia took place on 9 April.
“As a result of this collaboration, the combined distribution of Ellex and Quantel Medical product portfolios across Australia are able to offer a suite of advanced treatment solutions to drive greater value to ophthalmologist customers,” a company statement said.
“The shared heritage in the development of global, cutting-edge technologies will enable Ellex and Quantel Medical to better meet the needs of physicians and their patients. Both the applications and positioning of the two comprehensive product ranges will provide some of the most advanced ophthalmic treatment solutions covering a broad range of pathologies.”
Meanwhile, to support the Ellex and Quantel Medical merger, Mr Patrick Maine has been appointed to lead Ellex in Australia as CEO. He is being tasked with accelerating the integration of both businesses and strengthening the group’s position as a global ophthalmic leader.
He has significant senior executive experience within the laser industry for science, defence and medical applications, spanning across Europe and the US within parent company Lumibird Group, where he has recently held the position of chief technology officer for the past four years.
“It is really exciting for me to help Ellex and Lumibird Medical take full advantage of their combined strengths, providing both a global footprint for all our Medical products, and unmatched multi-centre R&D and manufacturing capabilities,” Maine said.